Other Information.
−Removed: On February 11, 2021, upon recommendation by the Compensation Committee, the Board approved the payment of retention bonuses of $56,000 to John Liatos and $41,250 to Steve Rychnovsky.
−Removed: The retention bonuses will be payable on the first business payment cycle following the end of our 2021 fiscal year, or earlier upon Board discretion.
−Removed: On February 11, 2021, upon recommendation by the Compensation Committee, the Board approved the modification of the Company’s vacation policy from an accrual-based policy to an unlimited policy, which eliminates the need for an accounting liability for accrued vacation.
−Removed: First Amended Executive Employment Agreement, by and between Kintara Pharmaceuticals, Inc.
−Removed: and Saiid Zarrabian (incorporated by reference to Exhibit 10.1 to the Company’s quarterly report on Form 10-Q filed with the SEC on November 12, 2020)†
Certification of principal executive officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *
10 unchanged sentences
Furnished herewith
−Removed: Exhibit is a management contract or compensatory plan or arrangement.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Kintara Therapeutics, Inc.
−Removed: February 12, 2021
/s/ Saiid Zarrabian
2 unchanged sentences
(Principal Executive Officer)
−Removed: February 12, 2021
/s/ Scott Praill
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.